2021 TSCRS共识:转移性结直肠癌的治疗

2021-11-15 台湾结直肠外科医师学会 Front Oncol

2021年11月,台湾结直肠外科医师学会(TSCRS)发布了转移性结直肠癌的治疗共识。转移性结直肠癌(mCRC)的治疗方案近年来发生了显著变化,本文主要诊断mCRC的治疗提供共识指导。

中文标题:

2021 TSCRS共识:转移性结直肠癌的治疗

英文标题:

Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment

发布日期:

2021-11-15

简要介绍:

2021年11月,台湾结直肠外科医师学会(TSCRS)发布了转移性结直肠癌的治疗共识。转移性结直肠癌(mCRC)的治疗方案近年来发生了显著变化,本文主要诊断mCRC的治疗提供共识指导。内容涉及患者的选择标准、治疗目标、分子特征的治疗考虑以及最佳治疗方案的选择。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 TSCRS共识:转移性结直肠癌的治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=0f1bd1c0022855fd, title=2021 TSCRS共识:转移性结直肠癌的治疗, enTitle=Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment, guiderFrom=Front Oncol, authorId=0, author=, summary=2021年11月,台湾结直肠外科医师学会(TSCRS)发布了转移性结直肠癌的治疗共识。转移性结直肠癌(mCRC)的治疗方案近年来发生了显著变化,本文主要诊断mCRC的治疗提供共识指导。, cover=https://img.medsci.cn/2021127/1638871548575_1608702.jpg, journalId=0, articlesId=null, associationId=2208, associationName=台湾结直肠外科医师学会, associationIntro=台湾结直肠外科医师学会(TSCRS,Taiwan Society of Colon and Rectal Surgeons), copyright=0, guiderPublishedTime=Mon Nov 15 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年11月,台湾结直肠外科医师学会(TSCRS)发布了转移性结直肠癌的治疗共识。转移性结直肠癌(mCRC)的治疗方案近年来发生了显著变化,本文主要诊断mCRC的治疗提供共识指导。内容涉及患者的选择标准、治疗目标、分子特征的治疗考虑以及最佳治疗方案的选择。</span></p>, tagList=[TagDto(tagId=439, tagName=消化道肿瘤), TagDto(tagId=5363, tagName=转移性结直肠癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=5363, guiderKeyword=转移性结直肠癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3633, appHits=246, showAppHits=0, pcHits=286, showPcHits=3387, likes=0, shares=27, comments=10, approvalStatus=1, publishedTime=Tue Dec 07 18:10:14 CST 2021, publishedTimeString=2021-11-15, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Tue Dec 07 18:05:54 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 18:16:09 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 TSCRS共识:转移性结直肠癌的治疗.pdf)])
2021 TSCRS共识:转移性结直肠癌的治疗.pdf
下载请点击:
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1205270, encodeId=33c812052e027, content=有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c212284887, createdName=121d314bm09暂无昵称, createdTime=Wed Mar 23 16:56:43 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199683, encodeId=cd181199683fc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d434691732, createdName=475455347, createdTime=Sat Mar 05 16:26:03 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199682, encodeId=9e7d11996823a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d434691732, createdName=475455347, createdTime=Sat Mar 05 16:25:30 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185801, encodeId=8f041185801fe, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77156473242, createdName=ms3000001389325032, createdTime=Tue Jan 18 22:33:21 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183375, encodeId=13e111833e52b, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a55449782, createdName=ms7000000226096118, createdTime=Tue Jan 11 21:55:58 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-03-23 121d314bm09暂无昵称

    有中文版吗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1205270, encodeId=33c812052e027, content=有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c212284887, createdName=121d314bm09暂无昵称, createdTime=Wed Mar 23 16:56:43 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199683, encodeId=cd181199683fc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d434691732, createdName=475455347, createdTime=Sat Mar 05 16:26:03 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199682, encodeId=9e7d11996823a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d434691732, createdName=475455347, createdTime=Sat Mar 05 16:25:30 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185801, encodeId=8f041185801fe, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77156473242, createdName=ms3000001389325032, createdTime=Tue Jan 18 22:33:21 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183375, encodeId=13e111833e52b, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a55449782, createdName=ms7000000226096118, createdTime=Tue Jan 11 21:55:58 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-03-05 475455347

    很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1205270, encodeId=33c812052e027, content=有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c212284887, createdName=121d314bm09暂无昵称, createdTime=Wed Mar 23 16:56:43 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199683, encodeId=cd181199683fc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d434691732, createdName=475455347, createdTime=Sat Mar 05 16:26:03 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199682, encodeId=9e7d11996823a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d434691732, createdName=475455347, createdTime=Sat Mar 05 16:25:30 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185801, encodeId=8f041185801fe, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77156473242, createdName=ms3000001389325032, createdTime=Tue Jan 18 22:33:21 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183375, encodeId=13e111833e52b, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a55449782, createdName=ms7000000226096118, createdTime=Tue Jan 11 21:55:58 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-03-05 475455347

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1205270, encodeId=33c812052e027, content=有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c212284887, createdName=121d314bm09暂无昵称, createdTime=Wed Mar 23 16:56:43 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199683, encodeId=cd181199683fc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d434691732, createdName=475455347, createdTime=Sat Mar 05 16:26:03 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199682, encodeId=9e7d11996823a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d434691732, createdName=475455347, createdTime=Sat Mar 05 16:25:30 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185801, encodeId=8f041185801fe, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77156473242, createdName=ms3000001389325032, createdTime=Tue Jan 18 22:33:21 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183375, encodeId=13e111833e52b, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a55449782, createdName=ms7000000226096118, createdTime=Tue Jan 11 21:55:58 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-01-18 ms3000001389325032

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1205270, encodeId=33c812052e027, content=有中文版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c212284887, createdName=121d314bm09暂无昵称, createdTime=Wed Mar 23 16:56:43 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199683, encodeId=cd181199683fc, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d434691732, createdName=475455347, createdTime=Sat Mar 05 16:26:03 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199682, encodeId=9e7d11996823a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d434691732, createdName=475455347, createdTime=Sat Mar 05 16:25:30 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185801, encodeId=8f041185801fe, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77156473242, createdName=ms3000001389325032, createdTime=Tue Jan 18 22:33:21 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183375, encodeId=13e111833e52b, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a55449782, createdName=ms7000000226096118, createdTime=Tue Jan 11 21:55:58 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-01-11 ms7000000226096118

    学习学习

    0

拓展阅读

2016 ESMO共识指南:转移性结直肠癌患者的管理

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2016-07-05

中国转移性结直肠癌患者二线治疗的系统性回顾及专家共识

中国肿瘤科相关专家小组(统称) · 2019-05-01

帕博利珠单抗对比化疗治疗微卫星高度不稳定或错配修复缺陷的转移性结直肠癌:KEYNOTE-177研究解读

中国科学院大学附属肿瘤医院(浙江省肿瘤医院)中国科学院基础医学与肿瘤研究所 · 2022-06-20

2022 加拿大共识实践指南:转移性结直肠癌的肿瘤生物标志物检测

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2022-07-20